CRIS Current Research Information System

MOLLICA, VERONICA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.895
EU - Europa 1.499
AS - Asia 1.234
AF - Africa 113
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 4.743
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.889
SG - Singapore 591
IT - Italia 508
CN - Cina 338
SE - Svezia 251
DE - Germania 138
GB - Regno Unito 136
CH - Svizzera 114
IN - India 103
VN - Vietnam 97
IE - Irlanda 88
FI - Finlandia 67
CI - Costa d'Avorio 65
BG - Bulgaria 42
RU - Federazione Russa 41
FR - Francia 37
JO - Giordania 31
ID - Indonesia 28
TG - Togo 28
NL - Olanda 24
PL - Polonia 12
JP - Giappone 11
NG - Nigeria 9
AT - Austria 8
HK - Hong Kong 7
TR - Turchia 7
ZA - Sudafrica 6
CA - Canada 5
PK - Pakistan 5
PT - Portogallo 5
UA - Ucraina 5
BD - Bangladesh 4
ES - Italia 4
HU - Ungheria 4
BE - Belgio 3
KR - Corea 3
PS - Palestinian Territory 3
RO - Romania 3
EE - Estonia 2
EG - Egitto 2
GH - Ghana 2
MY - Malesia 2
RS - Serbia 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
EU - Europa 1
GR - Grecia 1
LT - Lituania 1
LU - Lussemburgo 1
LV - Lettonia 1
MD - Moldavia 1
MX - Messico 1
PH - Filippine 1
SA - Arabia Saudita 1
SC - Seychelles 1
UZ - Uzbekistan 1
Totale 4.743
Salva come PNG Salva come JPEG
Città #
Singapore 495
Santa Clara 213
Boardman 181
Chandler 168
Bologna 130
Bern 111
Fairfield 109
Southend 107
Ashburn 93
Dublin 88
Abidjan 65
Princeton 61
Milan 54
Helsinki 53
Seattle 50
Turin 46
Houston 42
Sofia 42
Woodbridge 40
Cambridge 38
Wilmington 34
Boydton 33
Beijing 32
Amman 31
Dong Ket 28
Lomé 28
New York 26
Jakarta 25
Ann Arbor 24
Guangzhou 23
Shanghai 21
Los Angeles 20
Redmond 20
Berlin 19
Florence 19
Paris 16
Rome 15
Lappeenranta 14
Des Moines 13
Hyderabad 13
Redwood City 12
Bühl 11
Abeokuta 9
Jinan 9
San Diego 9
Westminster 9
Harbin 8
Zhengzhou 8
Arezzo 7
Monzuno 7
Nanjing 7
Shenzhen 7
Tianjin 7
Vienna 7
Warsaw 7
Brescia 6
Falls Church 6
Frankfurt am Main 6
Hong Kong 6
Moscow 6
Phoenix 6
Sant'Agata Bolognese 6
Telgate 6
Verona 6
Wuhan 6
Xi'an 6
Amsterdam 5
Bari 5
Chengdu 5
Hangzhou 5
Izmir 5
Nuremberg 5
San Polo di Torrile 5
Springfield 5
Budapest 4
Cagliari 4
Chongqing 4
Enschede 4
Falkenstein 4
Kumar 4
Miękinia 4
Modigliana 4
Mülheim 4
Olalla 4
Rimini 4
Washington 4
Bangalore 3
Brussels 3
Cardiff 3
Columbus 3
Council Bluffs 3
Genoa 3
Halhul 3
London 3
Modena 3
Montechiarugolo 3
Montefalco 3
Munich 3
Naples 3
Norwalk 3
Totale 2.960
Salva come PNG Salva come JPEG
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 178
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis 164
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 145
ECOG performance status ≥2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—A systematic review and meta-analysis of real world data 124
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 112
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 111
The human microbiota and prostate cancer: Friend or foe? 99
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 96
Is There a Role for Immunotherapy in Prostate Cancer? 89
Multi-Gene Next-Generation Sequencing Panel for Analysis of BRCA1/BRCA2 and Homologous Recombination Repair Genes Alterations Metastatic Castration-Resistant Prostate Cancer 84
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 83
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 82
Impact of HER2 assessment by CISH in urothelial carcinoma: A retrospective single-center experience 72
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 71
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 70
Renal Tumors with Oncocytic and Papillary Features: A Phenotypic and Genotypic Study 65
Comparative effectiveness of first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors according to IMDC risk groups in metastatic renal cell carcinoma: A meta-analysis 65
The functioning side of the pancreas: a review on insulinomas 64
H&E and OCT4/CD34 for the assessment of lympho-vascular invasion in seminoma and embryonal carcinoma 63
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 61
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 61
Third-and later-line treatment in advanced or metastatic gastric cancer: A systematic review and meta-analysis 59
Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough 58
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 57
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 57
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 55
A preliminary study investigating the detection of lymphovascular invasion in germ cell tumors of the testis with double staining for OCT4/CD34 53
Oncology clinical trials in the time of COVID-19: How a pandemic can revolutionize patients' care 52
Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data 50
Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials 49
Exploring the association between metastatic sites and androgen receptor splice variant 7 (AR-V7) in castration-resistant prostate cancer patients: A meta-analysis of prospective clinical trials 48
Immunohistochemical Expression of Preferentially Expressed Antigen in Melanoma (PRAME) in the Uninvolved Background Testis, Germ Cell Neoplasia in Situ, and Germ Cell Tumors of the Testis 46
SOX2 and PRAME in the "reprogramming" of seminoma cells 45
Quality of life assessment in renal cell carcinoma Phase II and III clinical trials published between 2010 and 2020: A systematic review 45
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 44
Bone targeting agents in patients with metastatic prostate cancer: State of the art 43
FoxA2 is a reliable marker for the diagnosis of yolk sac tumour postpubertal-type 41
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 41
Bone targeting agents, but not radiation therapy, improves survival in patients with bone metastases from advanced urothelial carcinoma receiving pembrolizumab: results from the ARON-2 study 40
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw 38
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy 38
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis 38
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis 37
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis 37
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience 37
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma 37
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study 35
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 35
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations 35
TAMs PD-L1(+) in the reprogramming of germ cell tumors of the testis 34
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 33
Microbiota and prostate cancer 33
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma 32
Mutations of NOTCH Genes as an Alternative Mechanism to Activate mTOR pathway in Low-grade Oncocytic Tumor (LOT) of the Kidney 32
Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report 32
Characterization of testicular embryonic-type neuroectodermal tumor and embryonic-type neuroectodermal tissue admixed with mature neuro-glial tissue using a broad immunohistochemical panel 31
Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis 31
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study 30
Yolk sac tumor of postpubertal-type does not exhibit immunohistochemical loss of SMARCB1/INI1 and SMARCA4/BRG1…but choriocarcinoma? 30
Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers 30
Cabazitaxel in metastatic prostate cancer 30
Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics 29
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System 29
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 29
A brand-new CAR for macrophages: Is it time to fire up the engines of a new era for the treatment of renal cell carcinoma? 28
Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma 27
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study 27
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 27
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer 26
A meta-analysis on overall survival and safety outcomes in patients with nonmetastatic castration-resistant prostate cancer treated with novel hormonal agents 26
Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy 26
Pembrolizumab plus enfortumab vedotin in urothelial cancer 25
The Impact of Concomitant Proton Pump Inhibitors on Immunotherapy Efficacy Among Patients with Urothelial Carcinoma: A Meta-Analysis 25
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study 24
Adjuvant treatment in renal cell carcinoma: a never-ending story? 24
Risk of toxicity with immunotherapy-tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials 24
Adapting to hormone-therapy resistance for adopting the right therapeutic strategy in advanced prostate cancer 24
Metabolomic profiling in renal cell carcinoma patients: News and views 23
Current androgen receptor antagonists under investigation for resistant prostate cancer 23
Evaluation of an institutional series of low-grade oncocytic tumor (LOT) of the kidney and review of the mutational landscape of LOT 23
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab 22
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 22
Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing 22
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 22
null 22
The dilemma of neoadjuvant and adjuvant therapy in urothelial carcinoma: Will immunotherapy solve the problem? 21
Treating prostate cancer by antibody-drug conjugates 21
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 20
An up-to-date evaluation of cabozantinib for the treatment of renal cell carcinoma 19
Re: WHO Classification of Tumours, 5th Edition, Volume 8: Urinary and Male Genital Tumours 19
Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors 19
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 19
Cancer immunotherapy: Current and future perspectives on a therapeutic revolution 19
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials 19
External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations 19
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? 18
Genomics and Immunomics in the Treatment of Urothelial Carcinoma 18
Peripheral nervous system adverse events associated with immune checkpoint inhibitors 18
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis 18
Adjuvant immunotherapy in muscle-invasive urothelial carcinoma 18
Totale 4.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.957
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.957
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020157 0 0 0 0 0 0 20 44 34 29 17 13
2020/2021358 31 8 14 44 27 8 1 20 37 25 11 132
2021/2022533 8 15 16 36 38 22 33 62 65 25 144 69
2022/20231.438 58 99 44 82 132 179 93 94 239 55 158 205
2023/2024753 87 96 64 65 51 100 22 78 40 57 46 47
2024/20251.734 149 429 312 220 411 141 72 0 0 0 0 0
Totale 5.067